SOSV is a global venture capital firm founded in 1995 and headquartered in New Jersey. The firm focuses on seed-to-growth investments in deep tech sectors, including biotech and life sciences, hardware and robotics, and cross-border software with emphasis on markets in Asia. It supports startups from early stages with investment capital as well as resources such as laboratories, collaborative spaces, and expert mentorship to accelerate product development and market traction. SOSV operates purpose-built programs to help portfolio companies raise follow-on funding, scale operations, and reach customers, often through structured matchmaking and access to a global network of investors. With a broad portfolio spanning hundreds of companies worldwide, SOSV aims to foster innovation, build vibrant entrepreneurial ecosystems, and contribute to sustainable technological advancement.

RA Capital Management is a Boston-based investment firm that provides multi-stage capital to public and private healthcare, life sciences, and planetary health companies. The firm supports management teams from early seed rounds to later financings, seeking to drive value through scientific and clinical data, product development, and commercialization. It complements capital with value-added services such as board representation, executive recruitment, and market intelligence through its TechAtlas research platform. The company also operates Raven, a healthcare incubator that helps entrepreneurs build biomedical ventures, and emphasizes a collaborative, data-driven approach and long-term relationships. RA Capital pursues social responsibility by advocating for affordable medicines and industry advancement, and it invests across U.S. and European opportunities, including early-stage and growth-stage rounds.

OrbiMed is a global healthcare investment firm based in New York that funds companies across the healthcare spectrum. It uses multiple strategies, including private equity for startups and growth-stage companies, private credit and royalty financing for intellectual property and medical diagnostics, and public equity investments. The firm targets biopharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and health IT, supporting development of new therapies and health technologies. OrbiMed operates internationally with offices in major markets and manages substantial assets across public and private investments, staffed by a team of professionals to identify opportunities and support portfolio companies.

Eli Lilly and Company is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of medicines for human health. It operates manufacturing facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in approximately 135 countries. The company also conducts research in animal health, including efforts to improve disease treatments in animals and the efficiency of animal food production. Its therapeutic focus includes neuroscience, cardiometabolic diseases, cancer, and immunology, with a portfolio of medicines addressing conditions such as cancer, diabetes, autoimmune disorders, and neurodegenerative diseases. Eli Lilly and Company is committed to high standards of safety and quality in manufacturing and to expanding access to therapies through global operations and patient support initiatives.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It invests in technology, consumer, and healthcare companies at early and growth stages, providing hands-on support and strategic resources in addition to capital. The firm has backed hundreds of portfolio companies and has a record of exits through IPOs and M&A, including unicorn and super unicorn companies. It maintains an international presence through a U.S. team established in 2017, with offices in Cambridge, Seattle, and San Francisco to support healthcare and life sciences entrepreneurs and help portfolio companies scale globally. Qiming emphasizes sector knowledge, founder collaboration, and a long-term partnership approach to drive milestone achievements and create lasting value.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven startups, especially in life sciences, biotechnology, healthcare, and related technologies. It backs companies co-founded by scientists and entrepreneurs and supports commercialization of innovations developed at academic research institutions and national laboratories. The firm takes a long-term, hands-on approach, leveraging its network to assist portfolio companies from inception to market realization and to build transformative enterprises. ARCH has raised ten venture funds totaling over $3 billion and has invested in more than 150 companies worldwide, reflecting a focus on strategic value creation and governance.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Samsara BioCapital is a Palo Alto, California-based biotechnology investment firm founded in 2016 that focuses on supporting transformative therapeutics. The firm seeks opportunities in the healthcare sector across the United States and invests in biotechnology companies with the potential to advance patient care. With a team drawn from scientific, medical, and business backgrounds, Samsara BioCapital aims to accelerate the development and commercialization of innovative drugs through strategic partnerships and hands-on collaboration. The approach emphasizes rigorous scientific evaluation and value creation for portfolio companies, helping entrepreneurs turn ideas into therapies with meaningful patient impact.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It focuses on technology and healthcare, investing in seed and early-stage companies in the United States and pursuing life sciences and emerging technologies. The firm provides funding and strategic guidance to entrepreneurs with the aim of building enduring, high-growth companies. Its portfolio has included notable technology and biotech names such as Apple, Illumina, Gilead Sciences, and DoubleClick. Venrock maintains offices in Palo Alto, California, and New York, and emphasizes long-term partnerships with founders to accelerate innovation.

Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines to address unmet medical needs. It maintains a broad portfolio across prescription medicines, vaccines, and treatments spanning internal medicine, inflammation and immunology, oncology, and other therapeutic areas, and it operates a sizable pipeline of investigational products with potential to address major diseases. The company conducts extensive global sales, with international markets contributing a substantial share of revenue, and it emphasizes scientific innovation, transparency, patient access, and ethical business practices. Its well-known products include Prevnar 13 and Eliquis, among others, and it continues to invest in research and development to advance new therapies. Based in the United States, Pfizer has a long history dating back to the 19th century and maintains a global footprint through manufacturing, partnerships, and philanthropic initiatives aimed at improving health outcomes worldwide.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health and the bioeconomy, spanning pre-clinical, early clinical and growth stages, and combines company building with venture capital while integrating ESG principles. With two decades of experience and about €5 billion under management across 11 funds, Forbion backs companies in Europe and North America across life sciences, pharmaceuticals and biotechnology sectors.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Redmile Group is a San Francisco based investment firm specializing in healthcare, life sciences and related technology sectors. It pursues venture, growth, and crossover investments and provides strategic capital and operating experience to portfolio companies, supporting growth initiatives, acquisitions, and strategic partnerships. With offices in San Francisco and New York, the firm takes a hands-on approach, applying deep industry knowledge and networks to help portfolio companies scale and create long-term value for investors.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Deep Track Capital is a Greenwich, Connecticut-based venture capital investment firm that concentrates on life sciences and biotechnology. It partners with management teams of innovative public and pre-IPO biotech companies, offering capital, strategic guidance, and access to its industry network. The firm aims to lead transactions, build large syndicates, and participate in rounds led by other investors, leveraging expertise in healthcare finance, biotech investing, and drug development to support portfolio companies through development and growth.

Logos Capital is a biotechnology-focused investment firm headquartered in San Francisco. The company applies disciplined, data-driven diligence across medical, scientific, and clinical disciplines to identify transformative therapies in healthcare. By combining in-house analytics with rigorous clinical evaluation, Logos Capital seeks to back life-changing therapeutics with strong value propositions. The firm emphasizes rigorous opportunity identification, thorough clinical trial underwriting, and proactive risk management, leveraging advanced analytics to predict trial outcomes and support informed investment decisions. Its approach aims to deliver compelling returns while contributing to patient outcomes by supporting companies with transformative technologies.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Deerfield Management is a New York-based healthcare investment firm established in 1994. It manages investments across public and private markets in healthcare products and services, including therapeutics, medical devices, diagnostics, digital health, and health services. The firm combines capital deployment with research and strategic intelligence through Deerfield Intelligence and supports innovation via Deerfield Discovery and Development (3DC) and a philanthropic foundation focused on education, healthcare access, and health outcomes.

Atlas Venture is a Cambridge-based venture capital firm with a 30-year history of building life sciences companies. Founded in 1980, it focuses on early-stage opportunities in biotechnology, biopharmaceuticals, diagnostics, medical devices, and related life sciences, as well as technology sectors. The firm uses a seed-led venture creation approach and often leads initial rounds, providing strategic guidance and board representation to portfolio companies. Its portfolio has included the development of more than 25 medicines and the launch of eight startups through its incubator program, and it has facilitated 43 IPOs and 39 M&A exits. Atlas operates with a global reach across the United States and Europe, supporting life science entrepreneurs in translating scientific advances into therapies and commercial opportunities.

Alumni Ventures is a venture capital firm founded in 2014 and based in Manchester, New Hampshire. It connects accredited individual investors with startup deals and co-invests alongside established venture capital firms across multiple stages, from seed to growth. The firm provides access to diversified portfolios through funds, syndicates, and investing clubs, supported by a large network of community members and individual investors. It invests across sectors and geographies, with a focus on transparency and due diligence in collaborative investments with leading firms such as Andreessen Horowitz, Sequoia, and Y Combinator. Alumni Ventures operates internationally with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo and has raised substantial capital to back founders with strategic capital and resources.

Illumina is a technology company that develops and sells instruments, reagents, and services for genetic analysis in life science and clinical laboratories. Its high-throughput sequencing platforms enable whole-genome sequencing in humans and other organisms, while lower-throughput systems support targeted applications such as viral and cancer screening. The company also markets microarrays for lower-cost, focused genetic screening with consumer and agricultural applications. Illumina generates over 90% of its revenue from sequencing instruments, consumables, and services, and its products and services support disease research, drug development, and the creation of molecular tests for clinical use, contributing to genomics-enabled personalized medicine.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a global portfolio of over 400 companies focused on healthcare and technology. It backs therapeutics, medtech, and healthtech and services as well as enterprise software, fintech, frontier tech and crypto, investing across the Americas, Europe and Asia and across stages from early to later as opportunities arise. The firm relies on a multidisciplinary team of scientists, engineers, physicians, operators and investors to help portfolio companies accelerate scalable growth and translate bold ideas into breakthroughs. With more than 50 years in operation and about $4.8 billion under management, F-Prime Capital provides strategic guidance and deep domain expertise to support ambitious teams worldwide.

SR One is the corporate venture capital arm of GlaxoSmithKline and a transatlantic biotechnology venture capital firm focused on translating innovative scientific discoveries into new medicines. It invests globally in life sciences companies pursuing breakthrough science that can significantly improve medical care, partnering with founders and entrepreneurs to move research from concept to therapy. The firm uses a back-and-build investment approach, prioritizing companies with strong fundamentals, clear development plans, and novel solutions to diseases, and it leverages its geographic reach on the West Coast of the United States and in London to provide strategic support and timely resources to portfolio companies. Since 1985, SR One has invested hundreds of millions of dollars in numerous companies, reflecting its role in bridging scientific innovation and medical progress.

IP Group is a global science and technology investment company that identifies, backs, and grows university spin-outs and IP-based businesses. Through strategic partnerships with universities and research institutions, it provides capital, expertise, and commercialization support to accelerate the development of innovations in healthtech, deeptech, and clean tech. The firm focuses on early-stage ventures, seeks to create value for shareholders and partners, and aims to generate financial returns alongside positive social and environmental impact in line with sustainable development goals. IP Group leverages its network, governance discipline, and portfolio-building capabilities to scale portfolio companies worldwide.

TCG Crossover is a science-driven venture capital firm focused on healthcare and biotechnology. It invests in biotechnology and pharmaceutical companies across the United States and Europe, supporting the development of medicines through a network of scientific advisors and resources that help navigate clinical and regulatory challenges. The firm has teams in Palo Alto and New York City and pursues long-term partnerships with entrepreneurs to translate cutting-edge science into meaningful patient outcomes.

Kurma Partners is a Paris-based European investment firm that finances innovation in healthcare and biotechnology. It backs companies across development stages, from early research to expansion, with a focus on therapeutic solutions, diagnostics, healthtech and medtech, as well as digital health. Operating across Europe, it collaborates with research institutes, hospitals and seasoned entrepreneurs to translate scientific advances into clinical and commercial products. The company invests in life sciences, pharmaceuticals and related technologies, emphasizing sustainable and responsible investing and close collaboration with research centers and entrepreneurs to accelerate breakthroughs in healthcare and create long-term value.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on early-stage investments in healthcare and biotech. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity in North America and Western Europe. The firm manages multiple funds and operates as a registered investment adviser, leveraging its network to support entrepreneurs and advance innovations in medicine and related technologies.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

Merck is a German chemical and pharmaceutical company founded in 1668 in Darmstadt, one of the world's oldest in its sector. It operates in three segments: Life Science, which provides laboratory consumables and instruments; Electronics, which supplies specialty materials for semiconductors and displays; and Healthcare, which develops branded pharmaceuticals with significant therapeutic focus in oncology, neurology and immunology (including multiple sclerosis), cardiovascular and fertility, complemented by patient devices and digital health solutions. The company has a global footprint across Europe, Africa, Asia, Oceania and the Americas. Outside the United States and Canada, the Merck name is used by this company, while in North America a separate company uses the Merck name (Merck & Co.). The founding family remains a majority owner of the company.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

SV Health Investors is a United States-based private investment firm focusing on healthcare and life sciences. Founded in 1993 (formerly SV Life Sciences), it operates across venture capital, growth equity and private equity, backing innovative therapeutics, biotechnology, medtech and healthcare services companies in North America and Western Europe. The firm provides capital and strategic support to entrepreneurs to build breakthrough companies, aiming to create value for patients and investors. With a global team of investment professionals and offices in Boston, San Francisco and London, SV Health Investors pursues opportunities across stages and geographies to advance medical innovation.

5AM Ventures is a San Francisco-based venture capital firm that makes seed- and early-stage investments in life sciences, healthcare, and related technology companies. The firm backs biopharmaceuticals, medical technology, and research instrument businesses and maintains a separate office in Boston. Founded in 2002 by John Diekman and Andrew Schwab, it concentrates on U.S. opportunities in healthcare and life sciences and pursues partnerships with academics and entrepreneurs to support discovery and development of breakthrough science.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including oncology and drug discovery. It supports startups from early discovery through commercialization, taking a long-term view to build companies around robust scientific platforms and multiple product opportunities rather than short-term exits. The firm emphasizes deep scientific expertise, strong teams, collaboration, and mentorship, exemplified by the Swanson Fellowship. It manages more than $4 billion in assets and has backed about 55 biotech companies, generating substantial returns and multiple exits. The organization operates a portfolio of funds to support its activities from discovery to market and maintains an edge-to-edge, long-term investment approach.

Boxer Capital is a biotechnology investment firm that invests in private and public companies across the full drug development lifecycle, from early discovery to late-stage clinical and commercial programs. Based in the United States, it operates as part of the Tavistock Group and concentrates on biotechnology, life sciences, and precision and specialized medicine. The firm emphasizes disciplined, science-driven analysis and a multidisciplinary approach, with bottom-up idea generation supported by experienced scientists, aiming to advance innovative targets and therapies that improve patient care. It pursues opportunistic venture investments across private and public markets.

Flagship Pioneering is a Cambridge, Massachusetts-based venture builder that conceives, creates, resources, and scales first-in-category companies in health, biotechnology, and sustainability. It turns early scientific breakthroughs into durable platforms and enterprises by combining scientific discovery with entrepreneurial leadership and capital management, pursuing transformative outcomes through an evolutionary approach. With more than 25 years of experience, Flagship builds ecosystems that connect science, startups, and collaboration across partners. Notable portfolio companies include Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, Lila Sciences, and Serif Biomedicines, reflecting a focus on pioneering medicines, intelligence, and preemptive health. The firm collaborates with major partners such as Genentech, Pfizer, GSK, Novo Nordisk, and Montai Therapeutics and engages in technology partnerships like AWS to accelerate discovery. Flagship emphasizes global health impact and disruptive science, fostering programs and opportunities through initiatives such as the Flagship Fellowship.

Nextech Invest is a Zurich-based investment firm dedicated to early-stage healthcare and life sciences companies, with a particular focus on oncology and precision medicine. It identifies and invests in emerging biotechnology ventures, providing support through scientific validation and value creation across the company’s lifecycle. The firm pursues opportunities globally, funding companies across continents and enabling technologies that advance therapies, diagnostics, and medical technologies. It operates independently in the life sciences and related fields and aims to build a portfolio of promising ventures with potential to improve cancer care and related healthcare outcomes.

Northpond Ventures is a science-driven venture capital firm specializing in growth capital, headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, it focuses on life sciences and technology sectors, including diagnostics, digital health, health tech, therapeutics, and artificial intelligence and machine learning. The firm backs growth-stage companies advancing biomedical research and technology-enabled healthcare, aiming to translate scientific advances into commercial solutions.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. It partners with entrepreneurs to fund and accelerate the development of novel therapeutics, translating scientific insight into strategic value for portfolio companies and aiming to bring life-saving medicines to patients. The firm seeks long-term collaborations across biology and chemistry to capture breakthroughs at the molecular level and expand the drug discovery toolkit.

DCVC is a venture capital investment firm founded in 2011 and based in Palo Alto, California. It concentrates on deep-tech opportunities across artificial intelligence, exascale computing, climate, engineering, materials science, robotics, space, water, biology, defense and security, and other advanced technologies. The firm operates as a registered investment adviser (RIA).

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.